Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Kyoichi Kaira,Yoshio Tomizawa,Hisao Imai,Reiko Sakurai,Masana Matsuura,Akihiro Yoshii,Mai Ochiai,Mie Kotake,Takeshi Ebara,Jun-ichi Saitoh,Noriaki Sunaga,Koichi Minato,Ryusei Saito,Takeshi Hisada

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

2017

Kyoichi Kaira
Yoshio Tomizawa
Hisao Imai
Reiko Sakurai
Masana Matsuura
Akihiro Yoshii
Mai Ochiai
Mie Kotake
Takeshi Ebara
Jun-ichi Saitoh
Noriaki Sunaga
Koichi Minato
Ryusei Saito
Takeshi Hisada

Background The aim of our study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin in combination with thoracic radiotherapy for patients with locally advanced stage III non-small cell lung cancer (NSCLC).

Keywords:

Carboplatin
Nab-paclitaxel
Paclitaxel
Cell
Radiation therapy
Lung cancer
Maximum tolerated dose
Oncology
Internal medicine
Medicine
locally advanced
thoracic radiotherapy
in patient
phase i study
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations